PURPOSE
Currently, no universally effective treatment exists to stop or reverse the development of liver fibrosis. Saxagliptin (SAX), a dipeptidyl peptidase-4 (DPP-4) inhibitor, has demonstrated extra-glycemic benefits, including anti-inflammatory and anti-apoptotic properties, but its role in hepatic fibrogenesis has...
M. Alsugoor, N. Alsuhaymi, S. El Awdan et al.· Toxicology Mechanisms and Me...· 0 citations
Abstract Objective Liver fibrosis is a progressive consequence of chronic injury with limited treatment options. Vildagliptin (Vilda), a dipeptidyl peptidase-4 inhibitor, possesses antioxidant and anti-inflammatory properties, but its effects on thioacetamide (TAA)-induced liver fibrosis are not fully characterized. Th...
Mohannad A. Almikhlafi, May A. Alsayb, Sara A. Almadani et al.· Immunopharmacology and immun...· 0 citations
In this exploratory model, remogliflozin was associated with attenuation of TAA-induced renal injury and modulation of related biomarkers, and warrants further preclinical investigation in TAA-associated renal injury.
Marwa M. Qadri, D. Almarghalani, Abdulaziz Alarifi et al.· Toxicology Mechanisms and Me...· 1 citation
Linagliptin demonstrates potent cardioprotective effects against cisplatin-induced toxicity, primarily through modulation of the SIRT1/AMPK/Nrf2 signaling pathway, thereby resulting in reduced oxidative stress and inflammation.
M. Alsugoor, N. Alsuhaymi, Bassim M. S. A. Mohamed et al.· Drug and chemical toxicology...· 0 citations
The results indicate that Lina protects against Cis‐induced liver damage by leveraging its antioxidant, anti‐inflammatory, and metabolic regulation properties.
M. A. Elbaset, Bassim M S A Mohamed, Passant E. Moustafa et al.· Advances in pharmacological...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
